Study Shows Osimertinib Improves Survival Following Surgery for Non-Small Cell Lung Cancer
A new study led by Yale Cancer Center shows improved rates of survival and reduced risk of recurrence in patients with non-small cell lung cancer taking osimertinib (TAGRISSO), a targeted therapy, following surgery. Non-small cell lung cancer...
7-Jun-2023 5:20 PM EDT
Add to Favorites